CG
UTHR icon

Cutler Group’s United Therapeutics UTHR Stock Holding History

Cutler Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,900
Closed -$10K – 5716
2022
Q1 		$10K Buy
+2,900
New +$552K ﹤0.01% 3639
2018
Q2 		– Sell
-3,000
Closed -$47K – 4928
2018
Q1 		$47K Buy
+3,000
New +$381K ﹤0.01% 1707
2017
Q4 		– Sell
-7,500
Closed -$48K – 5986
2017
Q3 		$48K Buy
7,500
+4,600
+159% +$587K ﹤0.01% 2283
2017
Q2 		$37K Sell
2,900
-600
-17% -$74.8K ﹤0.01% 2790
2017
Q1 		$52K Sell
3,500
-14,400
-80% -$2.18M ﹤0.01% 2379
2016
Q4 		$10K Buy
17,900
+4,400
+33% +$562K ﹤0.01% 4236
2016
Q3 		$51K Buy
13,500
+4,200
+45% +$505K ﹤0.01% 2455
2016
Q2 		$108K Sell
9,300
-2,100
-18% -$234K 0.01% 1619
2016
Q1 		$134K Buy
11,400
+200
+2% +$25.3K 0.01% 1339
2015
Q4 		$30K Buy
+11,200
New +$1.63M ﹤0.01% 3001

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Cutler Group's UTHR Position: Q3 2021 in Review

Cutler Group sold out of United Therapeutics (UTHR) in Q3 2021, closing a stake of 400 shares — an estimated $71K sold.

Cutler Group first reported a position in UTHR in Q1 2016 and held it in 14 quarters. The position peaked at $594K in Q1 2017. 426 funds tracked by Wall St. Rank hold UTHR as of Q3 2021.

  • Cutler Group reported no remaining United Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cutler Group sold 400 United Therapeutics shares in Q3 2021, an estimated $71K.
  • Cutler Group first reported a position in United Therapeutics in Q1 2016 and held it in 14 quarters.
  • Cutler Group's United Therapeutics position peaked at $594K in Q1 2017.
  • 426 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.